-
1
Phase 2 trial evaluated BeiGene’s PD-1 inhibitor, Tevimbra, in operable esophageal cancer.
-
2
Addition of Tevimbra before surgery led to higher pathological complete response rates.
-
3
44 patients in the Tevimbra group achieved a pathological complete response compared with 18.1% in the control group.
-
4
At 1 year, 95.6% of patients who received Tevimbra remained alive without disease progression.
-
5
The results may redefine the standard of care for treating operable esophagus tumors.
-
A phase 2 trial evaluated the use of BeiGene’s PD-1 inhibitor, Tevimbra, in patients with operable esophageal cancer following standard preoperative chemoradiation. The addition of Tevimbra before surgery led to a higher pathological complete response rate and promising progression-free survival trends, potentially redefining the standard of care for treating operable esophagus tumors.
-
1
Phase 2 trial evaluated BeiGene’s PD-1 inhibitor, Tevimbra, in operable esophageal cancer.
-
2
Addition of Tevimbra before surgery led to higher pathological complete response rates.
-
3
44 patients in the Tevimbra group achieved a pathological complete response compared with 18.1% in the control group.
-
4
At 1 year, 95.6% of patients who received Tevimbra remained alive without disease progression.
-
5
The results may redefine the standard of care for treating operable esophagus tumors.
Listen Tab content
